Hepatitis C virus treatment is often restricted in Medicaid [in Canada this would be PharmaCare] patients. This analysis evaluates the clinical and cost impacts of treating all Medicaid patients versus the current status quo.
The objectives of this study were to estimate change in chronic hepatitis C virus (HCV) disease and the economic burden associated with comprehensive treatment of the chronic HCV–infected Medicaid population.
As has long been predicted and as expected a “treat all” strategy in a Medicaid population resulted in superior SVRs, substantial reductions in downstream negative clinical outcomes, and considerable cost savings. Current restrictive state policies regarding HCV treatment in Medicaid populations must be reassessed in the light of these data.